European Commission Approves PBT2 Orphan Designation for Huntington’s Disease June 1, 2015August 16, 2022
Alterity Therapeutics Announces Regulatory Authorization to Proceed with ATH434 Phase 2 Clinical Trial in Italy June 23, 2022August 16, 2022